Windtree Therapeutics stock recently underwent a reverse split and published its quarterly financial results last week. The company does not currently pay dividends. The stock dropped by nearly 20% on Monday despite no specific news driving the decline.

Investors might be reacting to recent updates from Windtree Therapeutics, such as the reverse stock split last week to stay listed on Nasdaq, which can lead to more price instability. However, the decrease in share value suggests that shareholders are still concerned about the company's future.

Even after completing a $1.5 million convertible note bridge financing, the drug developer from Pennsylvania has seen its stock decrease. Windtree Therapeutics recently reported its fourth-quarter financial results, indicating a significantly reduced loss per share compared to predictions, but investors may still be uneasy about the lack of revenue generation.

With cash and equivalents of $4.3 million and $4.0 million in liabilities at the end of last year, Windtree Therapeutics also announced the purchase of specific assets from Varian Biopharmaceuticals Inc. Currently, Wall Street gives the stock a consensus "hold" rating as it does not pay dividends.